Tesamorelin,CJC1295 no dac,Ipamorelin
$273.00
CJC-1295 (DAC-free), also known as ModifiedGRF (1-29), is a 29 amino acid peptide that is a chemically synthesized analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a selective GH-Secretagogue and ghrelin, receptor agonist. Tesamorelin, a growth hormone-releasing analog, increased IGF-1 levels by an average of 181 micrograms per liter in both men and women.
Description
CJC-1295 (no DAC)
CJC-1295 (no DAC) also known as ModifiedGRF (1-29) is a peptide that comprises 29 amino acids and is a chemically synthesized analogue of growth-hormone releasing hormone (GHRH). This peptide is chemically similar to GHRH (it has amino acid substitutions at just 4 positions) but differs in the sense that it remains active in the blood-stream for a longer duration. CJC-1295 has been shown to increase growth hormone (GH) and insulin-like growth factor (IGF-1) in humans without any serious adverse reactions. A study conducted in 2001 showed that CJC-1295 was safe and generally well tolerated in patients who received a 14-day regimen that was delivered subcutaneously.
Ipamorelin
Ipamorelin is a selective GH-Secretagogue and ghrelin receptor agonist. The potency of ghrelin stimulation can be compared to GHRP6 with less appetite stimulation properties. However, unlike other GH-Secretagogues this pentapeptide doesn’t release the same volumes of cortisol, acetylcholine, prolactin and aldosterone. It is for this reason Ipamorelin has been considered the first selective GH-Secretagogue.
Tesamorelin
Tesamorelin is a growth-hormone-releasing analog that can increase IGF-1 levels in both men and women by an average of 181 micrograms/liter. This growth hormone can bind and stimulate the GHRH receptors that have a similar potency with GHRH. It binds and stimulates human GHRH receptors with similar potency as endogenous GHRH. It has a host of other benefits including nootropic effects and reducing triglycerides. Tesamorelin has subsequently been shown to decrease carotid intima media thickness (cIMT), visceral adipose tissue (VAT), and C-reactive proteins (CRP) in a recent study. It has not been shown to significantly affect other pituitary hormones and their respective mechanisms in the body. Additionally, it has been shown to improve cognitive function for healthy older adults and also for people with mild cognitive impairment who are at an increased risk of progressing to Alzheimer’s disease.
Summary
CJC-1295, Ipamorelin, and Tesamorelin are typically compounded together due to their ability to stimulate GHRH for enhanced results. Research reports accelerated fat loss, improved sleep, mood, increased energy, as well as long term growth hormone production with Ipamorelin. That is especially evident when programmatically combined with CJC 1295. After a cycle, the body sees a prolonged boost in hGH production far beyond their initial dose, thus allowing longer-term maintenance of benefits.
Tesamorelin also improves the overall framework of the body. This peptide works well for individuals 30+ since the production of GH naturally begins to lower as we age and it helps improve it. Physical activity supports the release of GH as well. This peptide is the mildest growth hormone-releasing peptide and also the most versatile one. It is said to be the most suitable peptide as it doesn’t induce these side effects like desensitization, hunger stimulation, or unnecessary plasma growth, like other peptides.
Research has shown that the net effect of combining the three peptides results in increased GH secretion and IGF-1 levels, increased muscle growth, increased bone density, improved cognitive function and memory, increased cellular repair and regeneration, increased fat loss, and more.
Referenced Citations:
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P. and Frohman, L. A. (2006) ‘Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults’, J Clin Endocrinol Metab,91(3), pp. 799-805.
Sackmann-Sala, L., Ding, J., Frohman, L. A. and Kopchick, J. J. (2009) ‘Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects’, Growth Horm IGF Res,19(6), pp. 471-7.
Onescu, M. and Frohman, L. A. (2006) ‘Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog’, J Clin Endocrinol Metab,91(12), pp. 4792-7.
Product use: This product is only for research chemicals.
Reviews
There are no reviews yet.